Combined kinase inhibition modulates parkin inactivation by Rubio de la Torre, Elena et al.
Combined kinase inhibition modulates
parkin inactivation
Elena Rubio de la Torre1, Berta Luzo´n-Toro1, Irene Forte-Lago1, Adolfo Minguez-Castellanos2,
Isidro Ferrer3 and Sabine Hilfiker1,
1Institute of Parasitology and Biomedicine ‘Lo´pez-Neyra’, Consejo Superior de Investigaciones Cientı´ficas (CSIC),
Granada, Spain, 2Department of Neurology, Virgen de las Nieves University Hospital, Granada, Spain and
3Institute of Neuropathology, IDIBELL-University Hospital Bellvitge, University of Barcelona, Llobregat, Spain
Received October 3, 2008; Revised and Accepted November 30, 2008
Mutations in the parkin gene cause autosomal-recessive, juvenile-onset parkinsonism, and parkin dysfunc-
tion may also play a role in the pathogenesis of sporadic Parkinson disease (PD). Although its precise func-
tion remains largely unknown, parkin seems to play a neuroprotective role. Several studies indicate that
changes in parkin solubility induced by post-translational modifications, such as S-nitrosylation or dopamine
modification, comprise one mechanism of parkin inactivation associated with disease. Protein phosphoryl-
ation events have recently been linked to the molecular mechanism(s) underlying PD, but the role of this
post-translational modification for parkin function has remained unclear. Here we report that compound
phosphorylation of parkin by both casein kinase I and cyclin-dependent kinase 5 (cdk5) decreases parkin
solubility, leading to its aggregation and inactivation. Combined kinase inhibition partially reverses the
aggregative properties of several pathogenic point mutants in cultured cells. Enhanced parkin phosphoryl-
ation is detected in distinct brain areas of individuals with sporadic PD and correlates with increases in
the levels of p25, the activator of cdk5. These findings indicate that casein kinase I and cdk5 may represent
novel combinatorial therapeutic targets for treating PD.
INTRODUCTION
Parkinson disease (PD) is a progressive and substantially
disabling neurodegenerative disorder (1–3). Its clinical
symptoms primarily result from the progressive and rather
selective degeneration of dopaminergic neurons of the sub-
stantia nigra pars compacta. Besides cell death, a pathological
hallmark of PD in surviving neurons comprises Lewy bodies,
ubiquitylated intraneuronal inclusions rich in a-synuclein (4).
Even though largely a sporadic disorder, there are several
genes associated with inherited forms of PD. One commonly
implicated is PARK2, the gene encoding for parkin (5).
Indeed, mutations in the parkin gene are responsible for a
large percentage of autosomal-recessive, juvenile-onset par-
kinsonism (6,7). A variety of homozygous and compound
heterozygous mutations have been reported, and although
mutations that reduce but do not abolish parkin function are
accompanied by dopaminergic cell loss in the presence of
Lewy bodies (8,9), homozygous loss-of-function parkin
mutations seem to be associated with a lack of Lewy bodies
(10), raising the possibility that parkin may be involved in
Lewy body biogenesis. Furthermore, parkin may also play a
role in sporadic PD, given that it is present in Lewy bodies
from sporadic PD patients (11,12).
Parkin functions as an E3 ubiquitin ligase (13), and inacti-
vation of its catalytic activity may lead to dopaminergic cell
death due to the accumulation of toxic substrate protein(s).
Recent studies suggest that changes in parkin solubility com-
prise a major mechanism of parkin inactivation both in famil-
ial and sporadic PD. For example, a wide range of pathogenic
parkin point mutations result in decreased parkin solubility
and promote its aggregation (14–16). In addition, an array
of oxidative stressors (17), as well as direct post-translational
parkin modifications, including dopamine modification (18) or
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S-nitrosylation (19,20), lead to dramatic changes in the solubi-
lity of parkin, thereby highlighting a mechanism for parkin
dysfunction in the pathogenesis of idiopathic PD.
Protein phosphorylation is another post-translational modifi-
cation which has recently been linked to mechanism(s) under-
lying PD (e.g. 21). As protein kinases are tractable drug
targets, these findings may help in the design of novel thera-
peutic strategies. Parkin has been previously described to be
subject to phosphorylation by casein kinase I or by cyclin-
dependent kinase 5 (cdk5), with modest changes in its enzy-
matic E3 ubiquitin ligase activity in either case (22,23).
Given that compound or hyperphosphorylation of proteins can
have profound effects on their aggregative properties, we
sought to determine whether compound phosphorylation of
parkin may modulate its aggregative properties. We hypoth-
esized that such phosphorylation-induced changes could
contribute directly to the inactivation of parkin and concomi-
tantly reduced survival of dopaminergic neurons in PD.
RESULTS
Compound phosphorylation of parkin in vitro and in cells
We first carried out in vitro phosphorylation experiments using
a set of purified protein kinases and recombinant full-length
human parkin protein, or select domains thereof (Fig. 1A
and B). Purified full-length parkin displayed both mono- and
polyubiquitylation activity in vitro (Fig. 1C) and was phos-
phorylated by casein kinase I (Fig. 1D–F), as previously
reported (22). Site-directed mutagenesis using full-length
parkin as well as parkin fragments confirmed that S101 and
S378 were phosphorylation sites for casein kinase I (22),
and an additional site was identified as S127 (Fig. 1D and
E). Indeed, mutations of these three serine residues to alanines
almost completely abrogated phosphorylation, indicating that
these sites are the major phosphorylation sites for casein
kinase I in vitro (Fig. 1D and F). Parkin was not an in vitro
substrate for a series of other protein kinases analyzed here
(Fig. 1G), indicating that only certain signal transduction cas-
cades may impact upon parkin function in vivo.
To assess phosphorylation of parkin in cells, we generated
phospho-state-specific antibodies against phospho-S101 and
phospho-S378. Their phosphorylation-state-specificity was
confirmed using recombinant, phosphorylated parkin protein
in vitro. The antibodies only detected the protein when pre-
viously phosphorylated by casein kinase I, but not its non-
phosphorylated form (Fig. 2A). Constitutive phosphorylation
of parkin on both S101 and S378 was detected when
HEK293T cells were transiently transfected with human
parkin (Fig. 2B). Upon treatment of transfected cells with
IC261, a selective inhibitor of casein kinase I (24,25), a sig-
nificant decrease in the phosphorylation state of both S101
and S378 of parkin was detected (Fig. 2C). Similarly, treat-
ment of transfected cells with 35 mM D4476 (26), a distinct,
structurally non-related and potent inhibitor of casein kinase
I led to a significant decrease in parkin phosphorylation (by
44+ 10%, mean+S.E.M., n ¼ 3) in the absence of measur-
able cytotoxicity. Together, these data indicate that S101
and S378 of parkin are phosphorylated by casein kinase I in
intact cells as well.
Apart from casein kinase I, parkin is also subject to phos-
phorylation by cdk5 on S131 (23). A phospho-mimetic
mutant on this site displayed enhanced casein kinase
I-mediated phosphorylation when compared with wild-type
in vitro (307+ 12%; mean+S.E.M., n ¼ 5) (Fig. 3A). Con-
versely, a phospho-mimetic mutant on all three casein kinase
I sites served as a better substrate for cdk5 when compared
with wild-type parkin in vitro (540+ 240%; mean+S.E.M.,
n ¼ 3) (Fig. 3B). Similar findings were observed in parkin-
transfected HEK293T cells using phospho-state-specific anti-
bodies. On the one hand, an S131E parkin mutant, which
mimicks constitutive phosphorylation by cdk5, displayed
enhanced phosphorylation by casein kinase I when compared
with wild-type parkin (Fig. 3C). On the other hand, blocking
the activity of cdk5 by treating transfected HEK293T cells
with roscovitine, a highly specific inhibitor for cdk5 (27),
decreased phosphorylation on the casein kinase I sites of
parkin (to 47+ 10%; mean+S.E.M., n ¼ 4) (Fig. 3D).
Together, these data indicate that phosphorylation of parkin
by cdk5 enhances its propensity to serve as a substrate for
casein kinase I and vice versa (Fig. 3E).
Effects of parkin phosphorylation on activity
and inclusion formation
Phosphorylation of parkin may regulate its E3 ubiquitin ligase
activity or modulate its insolubility, with downstream effects
on dopaminergic cell survival in either case. To determine
whether phosphorylation of parkin would affect its catalytic
activity, we performed autoubiquitylation assays in vitro
using various phospho-mimetic mutants (Fig. 4). A parkin
phospho-mimetic mutant for cdk5 phosphorylation (131E) dis-
played ubiquitylation activity similar to wild-type, whereas its
non-phosphorylatable counterpart (131A) was slightly more
active, as previously described (23) (Fig. 4A). Parkin phospho-
mimetic mutants for the individual casein kinase I sites (101E
or 378E) displayed ubiquitylation activity similar to wild-type
(Fig. 4B–D). Similarly, a phospho-mimetic mutant for all
three casein kinase I sites (101E/127E/378E) did not display
significant changes in ubiquitylation activity (Fig. 4E–G),
indicating that neither mimicking individual nor combined
phosphorylation of the casein kinase I sites affect parkin’s
ubiquitylation activity. A phospho-mimetic mutant for the
adjacent casein kinase I and cdk5 sites (127E/131E) did
not display changes in activity (Fig. 4C and D), whereas
a phospho-mimetic mutant for compound phosphorylation by
both casein kinase I and cdk5 (101E/127E/131E/378E)
displayed slightly enhanced autoubiquitylation activity
(Fig. 4E–G). However, this modest enhancement was also
observed for the respective non-phosphorylatable mutant
counterpart (101A/127A/131A/378A), and therefore does not
seem to reflect specific effects related to parkin phosphorylation
(Fig. 4E–G).
We next addressed whether parkin phosphorylation may
modulate its tendency to form inclusions in cell culture and con-
comitantly alter its solubility in detergent. For this purpose,
HEK293T cells were transfected with parkin or various
phospho-mimetic or non-phosphorylatable mutants, treated
with the proteasome inhibitor MG-132, and the amount of
parkin inclusion bodies determined by immunocytochemistry
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Figure 1. Parkin phosphorylation by casein kinase I in vitro. (A) Schematic representation of parkin domain structure, with domain boundaries shown by amino
acid residue numbers above, and of recombinant parkin domain combinations (full-length, N1–N3 and C1–C3) analyzed by in vitro phosphorylation assays.
(B) The different recombinant parkin domains were purified as described in Materials and Methods, and analyzed for purity by SDS–PAGE and Coomassie
staining. Full-length recombinant parkin as well as N1 and C3 truncated forms are indicated by arrows. Bacterial hsp70 (arrowhead), as determined by mass
spectroscopy, co-purified with full-length parkin. (C) Full-length recombinant parkin was catalytically active, as assessed by in vitro autoubiquitylation in
the presence of wild-type ubiquitin (Ub) or a lysine-less derivative (LL-Ub) lacking the conjugation sites necessary for polyubiquitylation. When the reaction
was performed with LL-Ub, lower levels of ubiquitylation were detected, indicating that recombinant parkin displays both multiple monoubiquitylation as well
as polyubiquitylation activity towards itself. (D) Full-length recombinant parkin (wt), or equal amounts of the indicated point-mutated versions (S101A, n ¼ 4;
S127A, n ¼ 4; S131A, n ¼ 4; S378A, n ¼ 4; S101A/S127A/S378A, n ¼ 3), were subjected to in vitro phosphorylation reactions using casein kinase I, and phos-
phate incorporation quantified by using a PhosphorImager (mean+S.E.M.). Note that the S101A mutant displayed increased phosphate incorporation in the
context of the full-length protein, possibly reflecting conformational effects. (E) The N1 fragment of recombinant parkin (wt) or equal amounts of the indicated
point-mutated versions (S101A, n ¼ 6; S127A, n ¼ 4; S101A/S127A, n ¼ 2) were subjected to in vitro phosphorylation reactions using casein kinase I, and
phosphate incorporation quantified by using a PhosphorImager (mean+S.E.M.). (F) Example of a phosphorylation experiment using full-length recombinant
parkin (wt) or the triple mutant S101A/S127A/S378A. (G) Parkin phosphorylation by additional protein kinases in vitro. Full-length recombinant parkin or
glutathione S-transferase-parkin (arrows) was subjected to in vitro phosphorylation reactions using cAMP-dependent protein kinase (PKA), PKC, Ca2þ/
calmodulin-dependent protein kinase II (CaM kinase II), GSK3b or ASK-1, as indicated, using various proteins as positive controls (synapsin, tau or MBP,
respectively) (arrowheads). None of these kinases significantly phosphorylated parkin in vitro.
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(Fig. 5A). Wild-type and all mutant parkin proteins were over-
expressed to similar degrees (Fig. 5B), and the parkin mutant
mimicking phosphorylation by only casein kinase I (101E/
127E/378E) or by only cdk5 (131E) did not show a significant
increase in the number of parkin inclusion bodies when com-
pared with wild-type (Fig. 5C). These results indicate that
individually mimicking phosphorylation by either casein
kinase I or by cdk5 does not lead to changes in parkin aggre-
gation. In contrast, a pronounced, 6.2+ 2-fold increase
(mean+S.E.M., n ¼ 4) in cells with parkin inclusions was
found with the parkin mutant mimicking compound phos-
phorylation by both protein kinases (101E/127E/131E/378E)
(Fig. 5C). Such enhanced aggregation was not observed with
a non-phosphorylatable mutant counterpart (101A/127A/
131A/378A) (Fig. 5C) and was only observed when mimick-
ing phosphorylation on all four serine residues (Fig. 5D),
indicating that it was specific for mimicking compound phos-
phorylation of parkin by both casein kinase I and cdk5.
An increased propensity of parkin to be confined to intra-
cellular aggregates should result in changes in its detergent
extractability, as previously described for several pathogenic
parkin mutants and stress-induced parkin alterations (14–
18). Indeed, although a significant amount of wild-type
parkin was found in the Triton-soluble fraction in the presence
of MG-132, the quadruple mutant mimicking compound phos-
phorylation displayed decreased solubility (Fig. 5E and F). In
contrast, no change in detergent extractability was observed
for the non-phosphorylatable mutant counterpart, which was
present in the soluble fraction to a degree similar to wild-type
parkin (Fig. 5E and F). Together, these data suggest that sim-
ultaneous phosphorylation of parkin on both casein kinase I
and cdk5 sites profoundly facilitates its aggregation into
inclusion bodies.
Increased phospho-parkin in Parkinson brain
To determine whether parkin undergoes phosphorylation in
human brain, and in sporadic PD, we chose to analyze
parkin and phospho-parkin levels from distinct brain areas
reported to be differentially affected by disease pathology
(28). Samples from three distinct brain areas were available
from each individual patient, and control and PD cases
matched for postmortem interval, tissue-handling and storage
conditions as important variables in these comparisons
(Fig. 6A). The levels of total parkin were similar in caudate,
cortex and cerebellum (Fig. 6B), and there were no differences
in the levels of total parkin between control and PD cases in
any of the three brain regions analyzed (Fig. 6C and D), as
previously described for cortical samples (29). However, we
found statistically significant increases in phospho-Ser101
parkin levels in PD versus control cases (Fig. 6C and D).
These increases were detected in the caudate, known to be par-
ticularly affected by the presence of Lewy bodies and Lewy
neurites during relatively early stages of disease development
(28). No significant changes in phospho-parkin levels in PD
versus control cases were observed in the cortex, and no
phospho-parkin could be detected in the cerebellum (Fig. 6C
and D), a brain area largely devoid of Lewy bodies and
Lewy neurites (27). Together, these data demonstrate a
neuroanatomical and disease-specific alteration in the phos-
phorylation status of parkin.
As a first step towards identifying the possible underlying
mechanism(s) for the differences in phospho-parkin levels in
PD when compared with control brains, we analyzed the
total levels of casein kinase I a, d and 1, as well as of
cdk5 and its activator p25/p35. Similar levels of the a and 1
isoforms of casein kinase I were detected in all three brain
areas, whereas the levels of the d isoform were lower in the
cerebellum when compared with caudate and cortex, as pre-
viously described (30) (Fig. 6B). Similar levels of cdk5 were
detected in all three brain areas, but the levels of p35 were
lower in the cerebellum when compared with caudate and
cortex, as previously described in rodent brain (31), and no
p25 could be detected in the cerebellum (Fig. 6B). No differ-
ences were observed in the levels of the three casein kinase
isoforms or of cdk5 in PD versus control in any of the three
brain areas analyzed (Fig. 6E and F). However, the total
levels of p25 were significantly higher in PD when compared
Figure 2. Parkin phosphorylation by casein kinase I in cells assessed using phospho-state-specific antibodies. (A) Phospho-state-specific antibodies against
phospho-S101 (P-Ser101) or against phospho-S378 (P-Ser378) recognize recombinant full-length parkin only upon its in vitro phosphorylation by casein
kinase I (þCK1), but not if the protein is not previously subjected to phosphorylation (2CK1). (B) Exogenous human parkin, upon transfection in
HEK293T cells (þtransf.), is constitutively phosphorylated on both S101 and S378 residues. Cells were treated for 1 h with 500 nM okadaic acid before cell
lysis to stabilize the phosphorylation state of parkin. (C) Exogenous human parkin phosphorylation on S101 and S378 decreases upon treatment of
HEK293T cells with IC261 (50 mM), a specific inhibitor of casein kinase I.
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with control samples in the caudate, with no changes in the
cortex (Fig. 6C and D). Thus, the observed increase in
phospho-parkin levels in PD when compared with control
may, at least in part, be due to changes in the total levels of
p25 in the distinct brain areas analyzed, with concomitant
changes in cdk5 activity followed by compound parkin
phosphorylation and aggregation.
Modulation of mutant parkin aggregation by
a combination of kinase inhibitors
As increased parkin phosphorylation seems to correlate with
sporadic PD in vivo and enhances the aggregative properties
of parkin in cultured cells, inhibiting casein kinase I and
cdk5 activities may have beneficial effects in preventing
such protein aggregation. To address this possibility, we quan-
tified the number of aggregates in cells transfected with three
pathogenic parkin mutants (R256C, R275W, C289G) pre-
viously described to display enhanced aggregative properties
when compared with wild-type parkin (14–16). Indeed, all
three mutants showed an enhanced propensity to form intra-
cellular aggregates in the absence of proteasome inhibition,
with C289G.R275W.R256C (Fig. 7A). These pathogenic
mutants did not display significant differences in their auto-
ubiquitylation activity (Fig. 7B) and were subject to phos-
phorylation by casein kinase I and cdk5 in vitro (Fig. 7C),
indicating that their major pathogenic mechanism of action
seems to involve enhanced aggregation. Concomitant with
their reduced detergent extractability, we observed that they
were present in the Triton-insoluble fraction in a heavily phos-
phorylated manner (Fig. 7D). Therefore, we next studied
whether inhibiting casein kinase I and cdk5 activities may
modulate the aggregative properties of these mutant proteins.
Cells were transfected with the aggregative R256C mutant
and analyzed 72 h after transfection. Around 20% of trans-
fected cells displayed large perinuclear inclusions, and treat-
ment of cells during the last 12 h using two structurally
dissimilar cdk5-specific inhibitors (roscovitine and GW8510
(32)), or two distinct casein kinase I-specific inhibitors
(CKI-7 (24,25)) and D4476 (25,26)) profoundly decreased
the number of cells with R256C-mutant parkin aggregates
(Fig. 8A). Statistically significant additive effects in decreas-
ing the number of cells with aggregates were observed when
using combinations of a cdk5-specific and a casein kinase
I-specific inhibitor (Fig. 8A), further indicating that the
effects were specific for inhibiting the activity of these two
protein kinases. The extent of the additive effect was relatively
small, in agreement with the observed crosstalk between
casein kinase I and cdk5 phosphorylation of parkin observed
in vitro (Fig. 3). Compound inhibition of cdk5 and casein
kinase I activities resulted in a roughly 70% decrease in the
number of cells displaying aggregates for the R256C mutant,
when compared with a 25% decrease for the R275W
mutant, with no effects observed for the most aggregative
C289G mutant (Fig. 8B). Addition of a casein kinase I-specific
and a cdk5-specific inhibitor decreased the phosphorylation
status of the three pathogenic parkin mutants analyzed to a
similar degree (Fig. 8C and D), indicating that the relative
efficiency by which compound kinase inhibition affects
aggregation of the respective mutants is likely due to the
observed distinct inherent aggregative properties of the
mutants (Fig. 7A).
As the C289G-parkin mutant accumulated in perinuclear
aggregates in virtually all transfected cells (Fig. 8B), we
reasoned that the effects of inhibiting parkin phosphorylation
may be best studied by analyzing the size and number of aggre-
gates for this potent aggregative parkin mutant. Indeed,
although treatment of transfected cells during the last 12 h
Figure 3. Compound phosphorylation of parkin in vitro and in cells.
(A) Example of an in vitro phosphorylation experiment using full-length
recombinant parkin (wt), or the indicated point-mutated versions (S131A,
S131E), and casein kinase I (CK1). (B) Example of an in vitro phosphorylation
experiment using full-length recombinant parkin (wt), or the indicated point-
mutated versions (S101A/S127A/S378A, S101E/S127E/S378E), and cdk5.
Arrows, full-length parkin and mutant versions thereof; arrowhead, bacterial
hsp70. (C) HEK293T cells were transfected with either wild-type (wt) or
S131E-mutant parkin, and equal amounts of cell extracts analyzed for
parkin phosphorylation using phospho-state-specific antibodies. (D) Parkin-
transfected HEK293T cells were treated with or without roscovitine (1 mM)
for 12 h, and equal amounts of cell extracts analyzed for parkin phosphoryl-
ation using phospho-state-specific antibodies. (E) Schematic model depicting
how parkin phosphorylation by one kinase may increase its propensity to serve
as a substrate for the other kinase, thereby leading to a multiple-
phosphorylated state.
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using distinct cdk5 inhibitors, casein kinase I inhibitors or a
combination thereof did not decrease the number of cells with
mutant parkin inclusions, we observed a decrease in the
number of cells displaying a large perinuclear aggregate
(Fig. 8E). The effects of individual inhibitor treatment were sig-
nificant on its own, and statistically significant additive effects
were observed when using a combination of both inhibitors,
with a nearly 50% reduction in the number of cells with large
perinuclear aggregates (Fig. 8E). In addition, prolonged and
repetitive incubation of cells with a mixture of a cdk5-specific
and a casein kinase I-specific inhibitor resulted in additive
beneficial effects in decreasing the number of cells with large
C289G-mutant parkin aggregates with time (Fig. 8F). Together,
these data show that inhibiting compound phosphorylation
of parkin can regulate its aggregative properties in culture,
indicating that such treatment is useful in maintaining
parkin’s protective function in cultured cells.
DISCUSSION
Here, we report that parkin, a protein essential for the sus-
tained survival of dopaminergic neurons, is subject to com-
pound phosphorylation in vitro and in cultured cells. Such
compound phosphorylation by casein kinase I and cdk5
enhances its insolubility, leading to aggregation and concomi-
tant inactivation. Although phosphorylation does not change
parkin’s E3 ubiquitin ligase activity, increased aggregation
effectively decreases the amount of soluble parkin protein
able to exert a neuroprotective role (33). Notably, only simul-
taneous, but not individual phosphorylation by either casein
kinase I or cdk5 seems to alter parkin solubility. Moreover,
phosphorylation of parkin by one kinase seems to enhance
its susceptibility to serve as a substrate for the other kinase.
In this manner, simultaneous activation of both kinases may
cooperatively contribute towards parkin inactivation.
Figure 4. Phosphomimetic parkin mutants do not display drastic changes in E3 ligase activity. (A) Example of an autoubiquitylation experiment using wild-type,
131A-mutant or 131E-mutant parkin forms, displaying enhanced activity of the 131A-mutant. (B) Example of an autoubiquitylation experiment using wild-type,
378A-mutant or 378E-mutant parkin forms and either using ubiquitin (Ub) or a lysine-less derivative (LL-Ub) to assess polyubiquitylation versus monoubiqui-
tylation activity, respectively. (C) Quantification of experiments of the type depicted in (B), indicating that the individual mutants do not lead to significant
changes in the ubiquitylation activity of parkin. The ubiquitin-positive ladder obtained with various parkin-mutant proteins and wild-type ubiquitin was quanti-
fied, values were corrected for differences in protein input as analyzed separately using an anti-parkin antibody (844) and normalized to the activity of wild-type
parkin. Bars depict mean+S.E.M. (D) Quantification of experiments of the type depicted in (B), indicating that the individual mutants do not lead to significant
changes in the monoubiquitylation activity of parkin. The ubiquitin-positive ladder obtained with various parkin-mutant proteins and lysine-less ubiquitin,
reflecting multiple mono-ubiquitylation activity, was quantified, corrected for differences in protein input and normalized to the activity of wild-type parkin.
Bars depict mean+S.E.M. N.A., not analyzed. (E) Example of an autoubiquitylation experiment using wild-type or the indicated parkin mutants (AAA,
101A/127A/378A; EEE, 101E/127E/378E; 131A-AAA, 101A/127A/131A/378A; 131E-EEE, 101E/127E/131E/378E), and either wild-type ubiquitin (Ub) of
a lysine-less derivative (LL-Ub) to assess monoubiquitylation activity. (F) The ubiquitin-positive ladder obtained with various parkin-mutant proteins (131E,
n ¼ 3; 131A, n ¼ 2; AAA, n ¼ 3; EEE, n ¼ 3; 131A-AAA, n ¼ 4; 131E-EEE, n ¼ 4) and wild-type ubiquitin was quantified. Values were corrected for differ-
ences in protein input as analyzed separately using an anti-parkin antibody (844), and normalized to the activity of wild-type parkin. Bars depict mean+S.E.M.
P , 0.05. (G) The ubiquitin-positive ladder obtained with various parkin mutant proteins (AAA, n ¼ 3; EEE, n ¼ 3; 131A-AAA, n ¼ 4; 131E-EEE, n ¼ 4) and
lysine-less ubiquitin, reflecting multiple mono-ubiquitylation activity, was quantified, corrected for differences in protein input and normalized to the activity of
wild-type parkin. Bars depict mean+S.E.M. Error bars are only depicted when larger than column lines. The 131A-AAA and 131E-EEE mutants displayed a
significant increase in autoubiquitylation activity only as assessed using ubiquitin, but not lysine-less ubiquitin.
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To assess whether parkin phosphorylation may occur in
humans, we analyzed samples from caudate nucleus, cortex
and cerebellum of control and PD brains. We observed
enhanced parkin phosphorylation in PD when compared with
control in the caudate, with no changes in the cortex. Of
note, parkin phosphorylation could not be detected in the cer-
ebellum in either control or PD samples. The neuroanatomical
differences in parkin phosphorylation between control and
sporadic PD samples correlate with the relative extent to
which these distinct brain areas are affected by disease patho-
logy (28), indicating that abnormal parkin phosphorylation
and concomitant inactivation may contribute to neuronal
degeneration in sporadic PD.
We further examined whether the increase in parkin
phosphorylation in PD brains may correlate with increases in
the levels of cdk5, its activator p25/p35 or casein kinase
I. Although we observed no changes in the levels of cdk5 or
the levels of distinct casein kinase isoforms, we did find an
increase in the levels of p25 in the caudate in PD when com-
pared with control samples, with no changes in the cortex and
the absence of detectable p25 in the cerebellum. In this
context, it is interesting to note that p25 is known to lead to
prolonged activation of cdk5 (34) and that cdk5 and p35
have been reported to accumulate in Lewy bodies in postmor-
tem PD brains (35,36). Furthermore, an increase in cdk5 levels
and activity has been observed in an 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine mouse model of PD (37), and
various neurotoxic insults induce generation of p25 from
p35 (38), indicating that the activity of cdk5 may play a key
role in the pathogenesis of sporadic PD (39).
Little is known regarding de-regulation of casein kinase I
activities during neurodegeneration (40), but most casein
kinase I isoforms seem to be basally active (41). Our present
data suggest that increased cdk5-mediated parkin phosphoryl-
ation would lead to a concomitant increase in casein kinase
I-mediated phosphorylation events, as detected here using
phospho-state-specific antibodies, thereby generating a com-
pound phosphorylated protein with decreased solubility.
Finally, the generally high basal casein kinase I and cdk5
activities suggest a very active role for protein phosphatases
in controlling the steady-state levels of parkin phosphorylation.
Indeed, a variety of studies indicate that inhibition of
Figure 5. Phospho-mimetic parkin mutants display profound changes in aggregative properties. (A) HEK293T cells were transfected with 101E/127E/131E/
378E-mutant parkin, and treated with 5 mM MG-132 for 12 h prior to immunocytochemistry using a polyclonal anti-parkin antibody (844) (green). Nuclei
were stained with DAPI. Scale bar, 10 mm. (B) To assure equal levels of overexpression of wild-type and mutant parkin forms, cells were transfected with
the various forms as indicated and 50 mg of cell extracts were subjected to western blot analysis 72 h later using an anti-parkin antibody (Abcam) or an anti-
tubulin antibody to correct for differences in protein loading. Wild-type and mutant parkin constructs were overexpressed to similar degrees. (C) HEK293T cells
were transfected with wild-type parkin or various mutant forms, treated with 5 mM MG-132 for 12 h followed by immunocytochemistry as described above. The
percent of transfected cells displaying large perinuclear inclusions was determined by an investigator unaware of treatment groups, and the data plotted as
an overall fold-increase in the number of transfected cells displaying large perinuclear inclusions when compared with wild-type parkin-expressing cells
(131E; n ¼ 3; 131A; n ¼ 3; AAA, n ¼ 3; EEE, n ¼ 4; 131A-AAA, n ¼ 4; 131E-EEE; n ¼ 4). Bars depict mean+S.E.M. P , 0.05. Error bars are only depicted
when larger than column lines. (D) HEK293T cells were transfected with wild-type parkin or various mutant forms, treated with 5 mM MG-132 for 12 h followed
by immunocytochemistry. None of the combinations analyzed led to significant changes in the number of transfected cells with inclusions, indicating that only
the quadruple mutant parkin-variant mimicking compound phosphorylation by casein kinase I and cdk5 displays an increased tendency to aggregate. Bars depict
mean+S.E.M. (n ¼ 3). (E) Analysis of the distribution of overexpressed wild-type (wt) or mutant parkin variants (treated with 5 mM MG-132 for 12 h before
analysis) (total, T) in the Triton X-100-soluble (S) and insoluble pellet (P) fractions of HEK293T extracts upon blotting with an anti-parkin antibody (Abcam) or
an anti-actin antibody. (F) Quantification of experiments of the type depicted in (E), where the amount of protein in the supernatant, when compared with that in
the pellet, is plotted as % soluble parkin. Bars depict mean+S.E.M. (n ¼ 3).
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Figure 6. Selective increase in phospho-parkin and p25 in distinct areas of idiopathic PD brains. (A) Gender, age at death (years) and postmortem interval (PMI, h)
for the eight human brains analyzed here. (B) Relative levels of total parkin, casein kinase I isoformsa, d and 1, cdk5, p35 and p25 in three distinct brain areas from a
control patient, and of tubulin as a protein loading control. Overexposed blot shows the absence of detectable p25 levels in the cerebellum. (C) Levels of phospho-
parkin (P-Ser101), parkin, p35/p25 and tubulin as a protein loading control were analyzed in caudate, cortex and cerebellum from four control and four PD patients
which were matched for postmortem interval tissue collection. Arrows indicate parkin band, arrowheads indicate cross-reacting band detected with the anti-parkin
antibody (Abcam). (D) Levels of phospho-parkin, parkin and p25 were normalized to tubulin levels and plotted on a histogram (n ¼ 4; mean+S.E.M., P , 0.05).
Error bars are only depicted when larger than column lines. (E) Levels of casein kinase I1 (CK11), cdk5 and tubulin as a protein loading control were analyzed in
caudate, cortex and cerebellum from four controls and four PD patients matched for postmortem interval tissue collection. (F) Levels of CK1a, d and 1, cdk5 and p35
were normalized to tubulin levels and plotted on a histogram (n ¼ 4; mean+S.E.M.). Error bars are only depicted when larger than column lines.
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phosphatase activities, with concomitant hyperphosphorylation
of proteins, can lead to PD-related neurodegeneration (42,43).
Thus, a complex balance between kinase and phosphatase
activities, possibly in a cell-type and region-specific manner,
may be subject to acute and/or chronic regulation.
To determine whether inhibition of casein kinase I and cdk5
activities would display beneficial effects in decreasing the
aggregative properties of pathogenic parkin-mutant protein, we
chose to analyze three distinct point mutants whose patho-
genic mechanism of action seems to involve enhanced aggre-
gation (14–16). Importantly, using a combination of inhibitors
against casein kinase I and cdk5, we could decrease the
number of cells displaying parkin aggregates for two out of
three mutants tested (R256C and R275W). For the third point
mutant (C289G), which displayed the most dramatic aggregative
phenotype, combined kinase inhibition led to a decrease in the
number of cells displaying large perinuclear aggregates, indicat-
ing beneficial effects of such inhibitor treatment in modulating
the profound aggregation even of this pathogenic mutant.
In conclusion, our experiments indicate that regulating the
phosphorylation status of parkin has beneficial effects in
reducing parkin aggregation and concomitant inactivation.
Although future studies will be necessary to determine the
neuroprotective or beneficial effects of combined kinase
inhibition for PD subjects, the present results may have
additional implications for other approaches in treating this
neurodegenerative disorder, including gene replacement
(44,45) or transplantation therapies (46).
MATERIALS AND METHODS
Plasmid construction
Human full-length parkin was amplified by PCR (primer
sequences: 50-TTA TGA ATT CAT ATA GTG TTT GTC
AGG TTC AAC-30 and 50-TTT AAA GCT TTT ACA CGT
CGA ACC AGT GGT CCC-30) using a full-length piTrex
human parkin cDNA construct and cloned into the EcoRI/
HindIII restriction sites of the pGEX-KG vector (47). Con-
structs encoding sequences for the different human parkin
domains (N1, N2, N3, C1, C2, C3) were generated by PCR
using the piTrex parkin cDNA construct as a template and sub-
cloned into the pGEX-KG vector as described above. For
expression of parkin in mammalian tissue culture cells,
human full-length parkin was amplified by PCR and subcloned
into the EcoRI/XbaI restriction sites of the pCMV5-SV40-
hGH vector (48). Point-mutated constructs were generated
using the QuickChange Site-Directed Mutagenesis Kit
(Stratagene) according to the manufacturer’s instructions. The
entire coding sequences of all constructs used in this study
were verified by DNA sequencing. The sequences of all primers
used in the present study are available upon author’s request.
Figure 7. Analysis of pathogenic parkin mutants. (A) The percentage of transfected cells displaying parkin aggregates using wild-type or various pathogenic
parkin point mutants (wt, n ¼ 5; R256C, n ¼ 6; R275W, n ¼ 11; C289G, n ¼ 10). Bars depict mean+S.E.M. (B) Example of an autoubiquitylation experiment
using wild-type or the indicated parkin mutants, and either wild-type ubiquitin (Ub) or a lysine-less derivative (LL-Ub). (C) Example of in vitro phosphorylation
experiments using full-length recombinant parkin (wt), or the indicated point-mutated versions, and either casein kinase I (CK1, top) or cdk5 (bottom).
(D) Analysis of the distribution of overexpressed wild-type (wt) or the various mutant parkin proteins (total, T) in the Triton X-100-soluble (S) and insoluble
pellet (P) fractions of HEK293T extracts upon blotting with a phospho-state-specific parkin antibody (P-Ser378), an anti-parkin antibody (Abcam) or an anti-
actin antibody. Note that the phosphorylation status of wild-type parkin in the soluble and insoluble fractions could only be detected in the presence of okadaic
acid or upon prolonged exposure of the blot (not shown).
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Protein purification
All recombinant proteins were expressed as N-terminally
tagged glutathione S-transferase fusion proteins in Escherichia
coli BL21 DE3 cells and purified essentially as described (49)
with minor modifications as outlined below. A 5 ml overnight
culture of cells was diluted 200-fold and grown at 378C to an
OD600 of around 0.6. Cells were incubated at 168C for 15 min,
followed by induction with 0.1 mM IPTG for 16–20 h at 168C.
Bacteria were pelleted at 10 000g for 10 min at 48C, and the
cell pellet resuspended in 12 ml (per liter culture) of resuspen-
sion buffer (PBS containing 1% TX-100, 1 mM PMSF, 1 mM
DTT, 50 mg/ml RNAse, 50 mg/ml DNAse and 100 mg/ml
lysozyme). The cell resuspension was incubated for 30 min
at 48C on a rotary shaker, followed by three sonication
pulses (30 s each, separated by 30 s intervals) on ice. Upon
centrifugation at 16 000g for 20 min at 48C, the soluble frac-
tion was filtered through a 0.22 mm filter and diluted with
6 ml of PBS containing 1% TX-100, 1 mM PMSF and 1 mM
DTT (per liter of culture). Proteins were bound to glutathione
Sepharose beads (Pharmacia) (750 ml of packed beads per liter
of culture) for 2 h at 48C. Beads were washed two times in
PBS/1% TX-100, two times in PBS and two times in thrombin
elution buffer (50 mM Tris–HCl, pH 8, 150 mM NaCl, 2.5 mM
CaCl2, 0.1% (v/v) b-mercaptoethanol). Pelleted beads were
resuspended to a 50% slurry with thrombin elution buffer,
and protein eluted with 50 units of thrombin (from bovine
plasma; Sigma) per liter of culture for 1 h at 48C with
shaking. Purified proteins were dialyzed into PBS containing
1 mM DTT for 1 h at 48C and small aliquots of recombinant
parkin proteins were frozen at –208C and only thawed up
once. Protein concentration was determined by the BCA
assay (Pierce) according to the manufacturer’s instructions.
Protein purity of all protein preparations was determined by
Coomassie Blue staining, and in most cases was around
80–90%. In most cases, enzymatic activity of recombinant
Figure 8. Inhibition of parkin phosphorylation decreases mutant parkin aggregation. (A) The percentage of transfected cells displaying R256C-mutant parkin
aggregates were quantified in the absence (2) or presence of various kinase inhibitors, or combinations thereof, present for 12 h before fixation. Inhibitors used
included roscovitine (0.5 mM), GW8510 (0.25 mM), CKI-7 (150 mM) and D4476 (17.5 mM). Bars depict mean+S.E.M. (n ¼ 3). Statistically significant additive
effects were observed when using a combination of kinase inhibitors, when compared with individual inhibitor treatments. P , 0.1. (B) Quantification of the
percentage of transfected cells displaying R256C-mutant, R275W-mutant or C289G-mutant parkin aggregates in the absence (2) or presence (þ) of 0.25 mM
GW8510 and 17.5 mM D4476 (R256C, n ¼ 5; R275W, n ¼ 3; C289G, n ¼ 4). Bars depict mean+S.E.M. P , 0.1; P , 0.01. Error bars are only depicted
when larger than column lines. (C) Analysis of the phosphorylation status of parkin in HEK293T cells transfected with wild-type (wt) or mutant parkin variants,
treated without (2) or with (þ) 0.25 mM GW8510 and 17.5 mM D4476 for 12 h before analysis upon blotting with the phospho-Ser378 antibody (overexposed
blot to show phosphorylation of wild-type parkin), an anti-parkin antibody (Abcam) or an anti-tubulin antibody. (D) Quantification of experiments of the type
depicted in (C), where the amount of phospho-parkin in the presence of inhibitors, when compared with that in the absence of inhibitors, is plotted as % decrease
in phosphorylation. Bars depict mean+S.E.M. (n ¼ 3). (E) The percentage of transfected cells displaying C289G-mutant parkin aggregates (left) and the per-
centage of those cells displaying (at least) one large perinuclear aggregate (right) were quantified in the absence (2) or presence of various kinase inhibitors, or
combinations thereof, present for 12 h before fixation. Inhibitors used included roscovitine (0.5 mM), GW8510 (0.25 mM), IC261 (25 mM), CKI-7 (150 mM) and
D4476 (17.5 mM). Bars depict mean+S.E.M. (n ¼ 3). Statistically significant additive effects were observed when using a combination of kinase inhibitors,
when compared with individual inhibitor treatments. P , 0.05. (F) The percentage of transfected cells displaying C289G-mutant parkin aggregates (left)
and the percentage of those cells displaying (at least) one large perinuclear aggregate (right) were quantified in the absence (2) or presence of 0.5 mM roscovitine
and 150 mM CKI-7. Inhibitors were added 12 h before fixation (12 h), 24 and 12 h before fixation (24 h) or 36, 24 and 12 h before fixation (36 h).
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full-length parkin was assayed by autoubiquitylation reactions
(see below) before the protein was used in other assays.
In vitro phosphorylation assays
Various recombinant wild-type and point-mutated full-length
and truncated parkin proteins (1 mg) were subjected to
in vitro phosphorylation reactions using buffer and enzyme
conditions as outlined below. Phosphorylation by casein
kinase I (0.5 units recombinant rat casein kinase Id; New
England Biolabs) was performed in 50 mM Tris–HCl, 5 mM
DTT, 10 mM MgCl2, pH 7.5, using 20 ng casein as a positive
control. Phosphorylation by cyclin-dependent protein kinase 5
(cdk5) (20 ng of human full-length cdk5/p25; Upstate) was
performed in 8 mM MOPS/NaOH, 0.2 mM EDTA, 10 mM
Mg-acetate, pH 7.0, using 500 ng of histone H1 as a positive
control. Phosphorylation by casein kinase II (1 mg recombi-
nant human casein kinase II; New England Biolabs) was per-
formed in 20 mM Tris–HCl, 50 mM KCl, 10 mM MgCl2, pH
7.5, using 20 ng of casein as a positive control. Phosphoryl-
ation by cAMP-dependent protein kinase A (PKA) (2.5 units
of recombinant murine PKA; New England Biolabs) was per-
formed in 50 mM Tris–HCl, 10 mM MgCl2, pH 7.5, using 1 mg
of purified bovine synapsin I as a positive control. Phosphoryl-
ation by glycogen synthase kinase 3b (GSK3b) (1 mg
of recombinant human his-tagged GSK3b; Calbiochem)
was performed in 25 mM Tris–HCl, pH 7.5, 5 mM
b-glycerolphosphate, 12 mM MgCl2, 2 mM DTT, 100 mM
Na3VO4 using 100 ng of recombinant human tau protein (Cal-
biochem) as a positive control. Phosphorylation by 1 mg of
protein kinase C (PKC) was performed in 50 mM HEPES,
pH 7.4, 10 mM Mg-acetate, 1 mM EGTA, 1 mM EDTA,
1.5 mM CaCl2, 1 mM DTT, 50 mg/ml phosphatidylserine and
4 mg/ml diacylglycerol using 1 mg of bovine synapsin I as a
positive control. For phosphorylation by Ca2þ/calmodulin-
dependent protein kinase II (CaMKII), 2.5 units of recombi-
nant rat CaMKII (New England Biolabs) were activated for
10 min at 308C in a buffer containing 50 mM Tris–HCl, pH
7.5, 10 mM MgCl2, 2 mM DTT, 0.1 mM EDTA, 100 mM
ATP, 1.2 mM calmodulin and 2 mM CaCl2. One microgram
of recombinant parkin was diluted in the same buffer and sup-
plemented with 200 mM ATP, and 1 mg of bovine synapsin I
served as a positive control. Phosphorylation by apoptosis
signal-regulating kinase 1 (ASK1) (150 ng or recombinant
human ASK1; Upstate) was performed in 8 mM MOPS/
NaOH, 0.2 mM EDTA, 10 mM Mg-acetate, pH 7.0, using
1 mg of mouse myelin basic protein (MBP) (Sigma) as a posi-
tive control.
Unless otherwise stated, all reactions were carried out in a
final volume of 40 ml and were initiated by the addition of
ATP (final concentration of 100 mM) with trace amounts of
[g232P]ATP (GEHealthcare, specific activity 150 mCi/ml).
After 30 min at 308C with shaking (450 rpm), reactions were
terminated by the addition of 0.2 volumes of 5 sample
buffer and boiling for 5 min at 958C. Proteins were separated
by sodium dodecyl sulfate–polyacrylamide gel electrophor-
esis (SDS–PAGE) on 10% polyacrylamide gels (or 12.5%
gels for assays containing N1-parkin or C3-parkin domains),
followed by staining with Coomassie blue dye. Incorporation
of 32P was quantified using a PhosphorImager (Molecular
Dynamics) and corrected for background values. Differences
in protein amounts were quantified on Coomassie-stained
gels using QuantityOne (Bio-Rad) and corrected for back-
ground values, and radioactivity values were corrected for
differences in protein loading.
Autoubiquitylation reactions
Recombinant full-length parkin (1 mg) was incubated with
80–150 ng of E1 enzyme (His-E1, Biomol), 2 mg of E2
enzyme (His-UbcH7, Biomol) and 5 mg of ubiquitin
(Sigma), or lysine-less or methylated ubiquitin (Boston-
Biochem), in a buffer containing 50 mM Tris–HCl, pH 7.4,
2 mM ATP, 1 mM DTT and 5 mM MgCl2. The reactions were
conducted at 308C for 90 min with shaking (450 rpm) and
terminated by adding 0.2 volumes of 5 sample buffer and
heating for 5 min at 958C. Samples were resolved in 7.5%
SDS–PAGE gels, followed by immunoblotting using a mono-
clonal anti-ubiquitin antibody (clone 6C1, Sigma) at 1:1000
dilution overnight at 48C, and equal amount of protein
loading was assured by immunoblotting samples indepen-
dently with an anti-parkin antibody (844) at 1:1000 dilution
overnight at 48C.
Generation of anti-parkin and anti-phospho-parkin
antibodies
Antibodies against parkin and phospho-parkin were generated
in collaboration with PhosphoSolutions, Aurora, CO, USA.
Briefly, antibodies were generated in rabbits against human
parkin (around amino acids 400) (844) and against chemic-
ally phosphorylated S101 (EREPQS(phospho)LTRVDL)
and S378 (GEGECS(phospho)AVFEAS) peptides. Phospho-
state-specific antibodies were affinity-purified via sequential
chromatography on phospho- and dephospho-peptide affinity
columns. The p-Ser101 antibody was generally used to
detect phospho-parkin in human brain extracts, whereas the
p-Ser378 antibody was preferentially used to detect phospho-
parkin in transfected HEK293 cell extracts.
Cell culture, transfection and cell lysis
HEK293T cells were cultured in 100-mm dishes and grown at
378C in 5% CO2 in growth medium (Dulbecco’s modified
Eagle’s medium) with 4 mM glutamine and non-essential
amino acids (Sigma), 10% heat-inactivated fetal bovine
serum (Invitrogen), penicillin (100 units/ml) and streptomycin
(100 units/ml). Confluent cells were harvested using 0.05%
trypsin, 0.02 mM EDTA in PBS and subcultured at a ratio of
1:4 to 1:6. Cells at 50–60% confluency were transfected
using 8 mg of plasmid of interest and 80 ml of PolyFect
transfection reagent (Qiagen) per 100 mm dish according to
the manufacturer’s specifications for 4 h in growth medium,
followed by addition of a fresh medium.
For preparation of extracts, cells were collected 48 h after
transfection. Prior to collection, transfected cells were
treated with 1 mM roscovitine (Calbiochem) for 12 h to
inhibit endogenous cdk5 activity, with 50 mM IC261
(3-[(2,4,6-trimethoxyphenyl)methylidenyl]indolin-2-one)
(Calbiochem) for either 3 or 12 h to inhibit endogenous casein
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kinase I activity, or with 35 mM D4476 for 12 h to inhibit
endogenous casein kinase I activity. Cell viability was
assessed by visual inspection as well as by Trypan blue exclu-
sion assays. Although treatment of cells with 50 mM IC261 for
12 h caused a slight decrease in cell viability (by 3.6+ 1.6%,
mean+S.E.M., n ¼ 3), treatment of cells with IC261 for 3 h,
or treatment of cells with any other kinase inhibitor analyzed
in the present study did not display any effect upon cell viabi-
lity. Where indicated, cells were further treated with 0.5 mM
okadaic acid (Alomone Labs) for 1 h prior to processing to
inhibit endogenous phosphatase activity. Cells were rinsed
once in ice-cold PBS followed by resuspension in 1–1.5 ml
of lysis buffer per 100 mm dish (1% SDS in PBS containing
1 mM PMSF, 1 mM Na3VO4 and 5 mM NaF). Resuspended
cells were incubated for 15 min at 48C in a rotary shaker, soni-
cated twice (two pulses for 1 s each) and centrifuged at
13 500 rpm for 10 min at 48C. Protein concentrations of super-
natants were estimated using the BCA assay (Pierce), followed
by the addition of 0.2 volumes of 5 sample buffer and
boiling for 5 min at 958C. Samples were directly analyzed
on western blots, as freeze–thaws were found to abolish detec-
tion of phospho-parkin levels. Unless otherwise stated,
80–100 mg of total protein extracts were loaded per lane to
ensure sensitive detection of phospho-parkin levels.
For sequential fractionation studies, cells were collected
72 h after transfection. Cells were rinsed once in ice-cold
PBS, followed by resuspension in 4 ml ice-cold PBS and the
cell suspension equally split into two tubes. After centrifu-
gation for 5 min (1500 rpm, 48C), pellets were resuspended
in 400 ml of buffer (50 mM Tris–HCl, pH 8.0, 300 mM
NaCl, 1.5 mM MgCl2, 2 mg/ml chymostatin, 100 units/ml
aprotinin, 1 mM PMSF, 1 mM Na3VO4 and 5 mM NaF) either
containing 1% SDS (total) or containing 1% Triton X-100.
The latter tube was incubated for 10 min at 48C on a rotary
shaker, followed by centrifugation at 82 000g for 20 min at
48C. The supernatant (Triton-soluble) was removed, and the
pellet resuspended in 200 ml of buffer containing 1% SDS,
followed by repetitive sonication to obtain complete solubil-
ization (Triton-insoluble). Protein concentration was estimated
by the BCA assay (Pierce), and 40 mg of the total and the
Triton-soluble fractions and 20 mg of the Triton-insoluble
fractions were resolved by SDS–PAGE and analyzed by
means of Western blotting. Extracts were independently
analyzed using a rabbit anti-actin antibody (Sigma, 1:100) to
account for differences in protein loading.
Immunocytochemistry
HEK293T or HEK293T/17 cells were plated onto 6-well
plates at 40% confluency and transfected the following day
(60% confluency) using 2 mg of DNA and 20 ml of PolyFect
transfection reagent according to the manufacturer’s instruc-
tions. Transfected cells were re-plated the next day at a 1:2
or 1:3 ratio onto coverslips and processed for immunocyto-
chemistry 2 days later. Where indicated, cells were treated
with 5 mM MG-132 (carbobenzoxy-L-leucyl-L-leucinal)
(Calbiochem) for 12 h to inhibit proteasome activity, which
enhances aggresome formation. Cells were then fixed for
30 min at 378C with 4% (w/v) paraformaldehyde in PBS.
Cells were permeabilized in 0.5% Triton X-100 in PBS
(35 min washes) and preincubated in blocking buffer (10%
goat serum; Vector Laboratories) in 0.5% Triton X-100 in
PBS for 1 h at room temperature, followed by exposure to
primary antibody [1:1000, polyclonal rabbit anti-parkin
(844)] diluted in blocking buffer for 1 h at room temperature.
Cells were washed in 0.5% Triton X-100 in PBS and incubated
with goat anti-rabbit AlexaFluor-488-conjugated secondary
antibody (1:1000, Invitrogen), diluted in 0.5% Triton X-100
in PBS, for 1 h at room temperature, followed by washes in
0.5% Triton X-100 in PBS, PBS, H2O and a rinse in 70%
ethanol. Fixed cells were mounted using mounting medium
containing DAPI (Vector Laboratories) and visualized on a
Zeiss microscope using a 40 or 100 oil-immersion objec-
tive. Using this technique, transfection levels were usually
found to be around 60%.
To determine the percentage of transfected cells containing
parkin inclusions, cells overexpressing parkin were scored to
display either diffuse cytosolic or aggregate staining. In
addition, cells displaying aggregates were scored to either
display at least one large perinuclear parkin aggregate or
only multiple small aggregates. These values were used to
determine the percentage of cells with (at least one) large
inclusion. Perinuclear aggregates were independently verified
to be aggresomes by double-staining with a monoclonal anti-
vimentin antibody (1:200, clone V9, Sigma) and a goat anti-
mouse AlexaFluor-594-conjugated secondary antibody
(1:1000, Invitrogen). For all determinations, between 250
and 1000 transfected cells were analyzed, and in all cases,
additional analysis was performed by an observer blind to con-
ditions. Cells were also examined using a Leica TCS-SP5 con-
focal microscope and Leica Applied Systems (LAS-AF) image
acquisition software. Images were collected using single exci-
tation for each wavelength separately and channels sub-
sequently merged using Adobe Photoshop.
Human cases
All PD cases had suffered from classical parkinsonism and
none of them had apparent cognitive impairment or dementia.
The postmortem delay between death and tissue processing
was between 3 and 7.5 h. The pH of the brain was between
6.6 and 6.9 in all cases. One-half of the brain was immediately
cut on coronal sections, 1 cm thick, frozen in dry ice and
stored at 2808C until use.
All sporadic PD cases were tested for the G2019S LRRK2
mutation (50) and were also tested for the c.255delA mutation
in parkin (51) if their age at onset was before 55 years. None
of the samples analyzed here were positive for either mutation.
Variable phenotypes and mixed pathologies can be
observed in a significant fraction of postmortem cases, such
as the presence of Alzheimer’s disease-associated lesions
combined with a-synuclein pathology in diagnosed PD
cases, implying possible molecular crosstalks in protein aggre-
gation mechanisms (52). In addition, Lewy body pathology
has been observed in around 10% of brains from normal
elderly subjects (53). To assure that our control subjects do
not display Lewy body pathology and that our PD subjects
display a-synuclein pathology in the absence of Alzheimer
disease (AD)-related lesions, all samples were subjected to
an extensive neuropathological study. Analysis was carried
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out on de-waxed 4-mm-thick paraffin sections of the frontal
(area 8), primary motor, primary sensory, parietal, temporal
superior, temporal inferior, anterior gyrus cinguli, anterior
insular, and primary and associative visual cortices; entorhinal
cortex and hippocampus; caudate, putamen and globus palli-
dus; medial and posterior thalamus; subthalamus; Meynert
nucleus; amygdala; midbrain (two levels), pons and bulb;
and cerebellar cortex and dentate nucleus. The sections were
stained with hematoxylin and eosin, Kluever Barrera and,
for immunohistochemistry, to glial fibrillary acidic protein
(Dako, 1:250), CD68 (Dako, 1:100), bA-amyloid (Boehringer
Mannhein, 1:50), tau AT8 (Innogenetics, 1:500), tau 4R and
tau 3R (Upstate, 1:200 and 1:2000, respectively), phosphoryl-
ation-specific tau Thr181, Ser202, Ser214, Ser262, Ser396
and Ser422 (all Calbiochem, 1:100, except Thr181, 1:250),
aB-crystallin (Abcam, 1:100), ubiquitin (Dako, 1:200),
a-synuclein (Chemicon, 1:3000), phosphorylation-specific a-
synuclein Ser129 (WAKO, 1:2000) and nitrated/oxidized
a-synuclein (Zymed, 1:400). Following incubation with
the primary antibody, the sections were incubated with
EnVisionþsystem peroxidase for 15 min at room temperature.
The peroxidase reaction was visualized with diaminobenzidine
and H2O2. In all cases, control of the immunostaining included
omission of the primary antibody.
Neuropathological characterization of PD was according to
established criteria (54). All PD cases corresponded to stage 4
of Braak and Braak. This implies involvement of selected
nuclei of the medulla oblongata, pons and midbrain, amygdala
and nucleus basalis of Meynert. All cases showed marked loss
of neurons in the substantia nigra pars compacta exceeding
60%, whereas moderate pathology occurred in the caudate
and putamen. In no case did Lewy pathology involve the
frontal cortex. No cases of dementia with Lewy bodies, accord-
ing to the guidelines of the specialized international workshop
(55,56), were included in the present series. AD-related patho-
logy, including b-amyloid plaques and neurofibrillary tangles,
was absent in the present series. Control subjects showed
absence of neurological symptoms, metabolic and vascular
diseases, and the neuropathological study disclosed no abnorm-
alities including lack of PD- and AD-related pathology.
Human tissues and sample preparation
Freshly frozen brain samples from deceased human subjects
were collected at autopsy following informed consent from
the next of kin under a protocol approved by the local ethics
committee. Brain regions from each control and PD patient
analyzed included cortex, cerebellum and caudate. For all
samples, patient age, gender, time to postmortem tissue collec-
tion and postmortem pathological analysis was known.
Small sections of frozen tissue blocks were added to 700 ml
of lysis buffer (1% SDS in PBS, 1 mM PMSF, 1 mM Na3VO4
and 5 mM NaF) and lysed using a 7-ml Dounce homogenizer
with a Teflon pestle. Lysis was performed by applying slow
strokes during maximally one minute. For cerebellar
samples, an additional two pulses of sonication (1 s each)
were needed to fully solubilize the tissue. Homogenates
were subsequently centrifuged for 10 min at 13’500 rpm at
48C. Protein concentration of the supernatants was estimated
using a BCA assay (Pierce), and 0.2 volumes of 5 sample
buffer added to extracts and boiling for 5 min at 958C. Care
was taken to ensure extracts were highly concentrated
(.5 mg/ml) such that phospho-parkin levels could be deter-
mined using mini-gels. As mentioned above for transfected
tissue culture cell extracts, samples were directly analyzed
on western blots, as repetitive freeze–thaws were found to
abolish detection of phospho-parkin levels and 80–100 mg
of total protein extracts were loaded per lane to ensure sensi-
tive detection of phospho-parkin levels.
Western blotting
Proteins were resolved by SDS–PAGE, transferred onto poly-
vinylidene difluoride membranes (Hybond, GEHealthcare)
and probed with primary antibodies overnight at 48C. The fol-
lowing antibodies were employed: a rabbit polyclonal anti-
parkin antibody (1:1000 for cell and brain extracts, ab6177,
Abcam), a custom-made anti-parkin antibody 844 (1:1000
for recombinant proteins), an anti-phospho-S101-parkin anti-
body (1:200 for cell extracts and brain extracts) an
anti-phospho-S378-parkin antibody (1:500 for cell extracts;
1:5000 for recombinant proteins), anti-p35 (1:100, C-19,
Santa Cruz Biotechnology), anti-cdk5 (1:400, DC17, Santa
Cruz Biotechnology), anti-casein kinase I1 (1:250, BD
Transduction Laboratories), anti-casein kinase Ia (1:200,
C19, Santa Cruz Biotechnology), anti-casein kinase Id (1:50,
H60, Santa Cruz Biotechnology), anti-a-tubulin (1:5000,
clone DM1A, Sigma) and anti-actin (1:100, Sigma). Mem-
branes were washed and incubated with secondary antibodies
[anti-rabbit HRP-conjugated antibody (1:2000) or anti-mouse
HRP-conjugated antibody (1:2000) (Dako Cytomation)] for
90 min at room temperature, followed by detection using
ECL reagents (Roche).
Statistical analysis
Experiments were done the indicated amount of times, and the
data were analyzed using a Student’s paired t-test.
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